TY  - INPR
AV  - public
ID  - discovery10192167
KW  - Clinical trials
KW  -  Parkinson?s disease
KW  -  disease modification
KW  -  drug repurposing
KW  -  neuroprotection
N1  - © 2024 ? The authors. Published by IOS Press. This is an Open Access article distributed under the terms
of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0).
TI  - Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials initiative
SN  - 1877-7171
Y1  - 2024/04/05/
A1  - Wyse, Richard K
A1  - Isaacs, Tom
A1  - Barker, Roger A
A1  - Cookson, Mark R
A1  - Dawson, Ted M
A1  - Devos, David
A1  - Dexter, David T
A1  - Duffen, Joy
A1  - Federoff, Howard
A1  - Fiske, Brian
A1  - Foltynie, Thomas
A1  - Fox, Susan
A1  - Greenamyre, J Timothy
A1  - Kieburtz, Karl
A1  - Kordower, Jeffrey H
A1  - Krainc, Dimitri
A1  - Matthews, Helen
A1  - Moore, Darren J
A1  - Mursaleen, Leah
A1  - Schwarzschild, Michael A
A1  - Stott, Simon RW
A1  - Sulzer, David
A1  - Svenningsson, Per
A1  - Tanner, Caroline M
A1  - Carroll, Camille
A1  - Simon, David K
A1  - Brundin, Patrik
JF  - Journal of Parkinson's Disease
UR  - http://doi.org/10.3233/JPD-230363
PB  - IOS Press
N2  - In 2011, the UK medical research charity Cure Parkinson's set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson's disease (PD). The first committee meeting was held at the Van Andel Institute in Grand Rapids, Michigan in 2012. This group of PD experts has subsequently met annually to assess and prioritize agents that may slow the progression of this neurodegenerative condition, using a systematic approach based on preclinical, epidemiological and, where possible, clinical data. Over the last 12 years, 171 unique agents have been evaluated by the iLCT committee, and there have been 21 completed clinical studies and 20 ongoing trials associated with the initiative. In this review, we briefly outline the iLCT process as well as the clinical development and outcomes of some of the top prioritized agents. We also discuss a few of the lessons that have been learnt, and we conclude with a perspective on what the next decade may bring, including the introduction of multi-arm, multi-stage clinical trial platforms and the possibility of combination therapies for PD.
ER  -